Oxford Immunotec Reports Second Quarter 2016 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Oxford Immunotec Reports Second Quarter 2016 Financial Results
  • Second quarter revenue of $19.2 million, increased 34% compared to prior year period
  • Raising revenue guidance for the full year from $79.5-$82.5 million to $82.5-$84.5 million
  • Completed acquisition of Imugen, Inc. on July 1, 2016 for $22.2 million in all cash deal, accelerating entry into tick-borne disease testing market

OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD ), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced second quarter 2016 financial results.

“We are very pleased with our financial and operating results during the second quarter,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "Sales performance exceeded our expectations, with solid growth coming from the United States, China and Japan. Additionally, we are tremendously excited about the recent acquisition of Imugen, which accelerates our entry into the tick-borne disease market and marks a significant advance in our goal of becoming a leader in the field of immune-regulated conditions.”

By revenue type, total revenues were, in millions:

    Three Months Ended June 30,
        2016         2015     Percent Change
             
Product   $   9.3     $   6.6       41 %
Service       9.9         7.7       29 %
Total Revenue   $   19.2     $   14.3       34 %

By geography, total revenues were, in millions:

    Three Months Ended June 30,
            Percent Change
      2016       2015     As Reported   Constant Currency Basis
                 
United States   $   9.8     $   7.3       34 %     34 %
Europe & ROW       2.0         1.9       2 %     6 %
Asia       7.4         5.1       47 %     37 %
Total revenue   $   19.2     $   14.3       34 %     32 %

Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure “constant currency basis” in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. We consider the use of a period over period revenue comparison on a constant currency basis to be helpful to investors, as it provides a revenue growth measure free of positive or negative volatility due to currency fluctuations.

Second Quarter 2016 Financial Results

Revenue for the second quarter of 2016 was $19.2 million, representing 34% growth over the second quarter 2015 revenue of $14.3 million. On a constant currency basis, revenue growth was 32% versus the prior year period.

2016 second quarter product revenue was $9.3 million representing a 41% increase from product revenue of $6.6 million in the second quarter of 2015. The increase in product revenue was primarily attributable to growth in Asia. Service revenue for the second quarter of 2016 was $9.9 million, up 29% from 2015 second quarter revenue of $7.7 million. The increase in service revenue was primarily driven by volume increases in the United States.

United States revenue was $9.8 million in the second quarter of 2016 representing 34% growth over the same period's revenue of $7.3 million in the prior year. Growth was driven primarily by volume increases in the institutional and patient testing segments.

Europe & ROW revenue was $2.0 million in the second quarter of 2016 representing a 2% increase compared to the second quarter of 2015. On a constant currency basis, Europe & ROW increased 6% versus the second quarter of 2015.

Asia revenue was $7.4 million in the second quarter of 2016 representing 47% growth over 2015 second quarter revenue of $5.1 million. On a constant currency basis, Asia grew 37% versus the second quarter of 2015. The increase was driven by continued strong growth in China and Japan.

Gross profit for the second quarter of 2016 was $10.5 million, an increase of $2.8 million over gross profit of $7.8 million in the same period of 2015. Gross margin was 55.1%, an increase of 70 basis points from the gross margin of 54.4% in the second quarter of 2015. The increase in gross margin was primarily due to lower kit costs associated with increased volume, product mix and the favorable impact of exchange rates on average selling prices, partially offset by costs associated with new service initiatives.

Operating expenses were $17.9 million in the second quarter of 2016, an increase of $3.5 million compared to $14.4 million in the same period last year. The increase in operating expenses was primarily due to headcount increases related to both sales and marketing and general and administrative functions, clinical costs and legal expenses.

Net loss for the second quarter of 2016 was $6.4 million, or $0.29 per share, compared to $7.3 million, or $0.33 per share, in the second quarter of 2015. Net loss per share was based on 22,351,645 and 22,245,682 weighted average ordinary shares outstanding for the second quarters of 2016 and 2015, respectively. 

EBITDA for the second quarter of 2016 was $(5.8) million compared to $(6.8) million in the second quarter of 2015. Adjusted EBITDA was $(5.3) million for the second quarter of 2016 compared to $(6.5) million in the same period in 2015. Both EBITDA and Adjusted EBITDA are non-GAAP measures.

Cash and cash equivalents were $64.0 million as of June 30, 2016 compared to $68.7 million as of March 31, 2016. Cash usage during the quarter was in line with expectations. 

Imugen Acquisition

On July 1, 2016, the Company completed the acquisition of substantially all of the assets of Imugen, a Massachusetts-based clinical laboratory focused on developing and performing specialized testing for tick-borne diseases, for $22.2 million in an all cash transaction.

Business Outlook

We expect to report full year 2016 revenue of between $82.5 and $84.5 million as compared to our prior guidance of between $79.5 and $82.5 million.

We expect to report revenue of between $24.2 and $25.0 million for the third quarter of 2016.

We expect to have approximately $30 million in cash at the end of 2016, which will give the Company cash into the second half of 2018 based on our current operating plan.

Conference Call

Oxford Immunotec will host a conference call on Tuesday, August 2, 2016 at 8:00 a.m. Eastern Time to discuss its second quarter 2016 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 47066686 approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at  www.oxfordimmunotec.com . The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT ® . TB test, which is used to test for tuberculosis infection. The T-SPOT. TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT. CMV test and the T-SPOT. PRT test are the Company's second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has additional active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com .

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.

Forward-Looking Statements

This release contains forward-looking statements, including statements regarding future revenues, expenses and the prospects for sales of our products. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers, as well as our ability to expeditiously and successfully expand our sales and distribution networks and the other factors described under the "Risk Factors" section in our filings with the Securities and Exchange Commission. When evaluating Oxford Immunotec's business and securities, investors should give careful consideration to these risks and uncertainties.

Forward-looking statements are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

CONTACTS:

For Media Inquiries: Caroline Crawley Oxford Immunotec Tel: +44 1235 442796 ccrawley@oxfordimmunotec.com  

For Investor Inquiries: Rick Altieri Chief Financial Officer Oxford Immunotec Tel: +1 (508) 573-9953 raltieri@oxfordimmunotec.com  

Mark Klausner Westwicke Partners Tel: +1 (443) 213-0501 oxfordimmunotec@westwicke.com

Oxford Immunotec Global PLC Condensed consolidated statements of operations (unaudited)

    Three months ended June 30,   Six months ended June 30,
(in thousands, except share and per share data)     2016       2015       2016       2015  
Revenue                
Product   $ 9,293     $ 6,613     $ 17,431     $ 13,735  
Service      9,861        7,639        18,833        14,318  
Total revenue      19,154        14,252        36,264        28,053  
Cost of revenue                
Product      3,512        2,885        6,805        5,955  
Service      5,094        3,617        9,966        7,202  
Total cost of revenue      8,606        6,502        16,771        13,157  
Gross profit      10,548        7,750        19,493        14,896  
Operating expenses:                
Research and development      3,341        2,846        6,417        5,205  
Sales and marketing      9,391        7,727        17,871        15,168  
General and administrative      5,151        3,784        9,734        7,651  
Total operating expenses      17,883        14,357        34,022        28,024  
Loss from operations      (7,335 )      (6,607 )      (14,529 )      (13,128 )
Other income (expense):                
Interest expense, net      (17 )      (19 )      (34 )      (34 )
Foreign exchange gains (losses)      874        (674 )      1,237        (509 )
Other income (expense)      29        7        (137 )      114  
Loss before income taxes      (6,449 )      (7,293 )      (13,463 )      (13,557 )
Income tax (benefit) expense      (3 )      1        32        48  
Net loss   $ (6,446 )   $ (7,294 )   $ (13,495 )   $ (13,605 )
                 
Net loss per share attributable to ordinary shareholders—basic and diluted   $ (0.29 )   $ (0.33 )   $ (0.60 )   $ (0.64 )
                 
Weighted-average shares used to compute net loss attributable to ordinary shareholders—basic and diluted      22,351,645        22,245,682        22,318,019        21,293,835  
                 

Reconciliation of net loss to Adjusted EBITDA (1) (unaudited)

    Three months ended June 30,   Six months ended June 30,
(in thousands)     2016       2015       2016       2015  
Net loss   $ (6,446 )   $ (7,294 )   $ (13,495 )   $ (13,605 )
Income tax (benefit) expense      (3 )      1        32        48  
Interest expense, net      17        19        34        34  
Depreciation and amortization      624        483        1,205        936  
EBITDA      (5,808 )      (6,791 )      (12,224 )      (12,587 )
                 
Reconciling items:                
Share-based compensation expense      1,355        713        2,459        1,588  
Unrealized exchange gains      (896 )      (459 )      (1,418 )      (615 )
Change in fair value of contingent purchase price consideration      57        49        112        96  
Adjusted EBITDA   $ (5,292 )   $ (6,488 )   $ (11,071 )   $ (11,518 )
                 

(1) EBITDA and Adjusted EBITDA are non-GAAP measures that we calculate as net loss, adjusted for the impact of earnings or charges resulting from matters that we consider not to be indicative of our ongoing operations. We believe that these measures provide useful information to investors in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Our presentation of these measures is not made in accordance with U.S. GAAP, and our computation of these measures may vary from others in the industry. Our use of these measures has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP.

The above table presents a reconciliation of net loss, the most comparable U.S. GAAP measure, to EBITDA and Adjusted EBITDA for each of the periods indicated.

Oxford Immunotec Global PLC Condensed consolidated balance sheets (unaudited)

    June 30,   December 31,
(in thousands, except share and per share data)     2016       2015  
Assets        
Current assets:        
Cash and cash equivalents   $ 63,965     $ 83,715    
Accounts receivable, net      9,742        7,058    
Inventory      8,641        7,099    
Prepaid expenses and other      2,647        3,592    
Total current assets      84,995        101,464    
Restricted cash, non-current      80        80    
Property and equipment, net      6,561        6,284    
In-process research and development      1,814        1,782    
Goodwill      46        45    
Other intangible assets, net      143        179    
Other assets      19        18    
Total assets   $ 93,658     $ 109,852    
         
Liabilities and shareholders’ equity        
Current liabilities:        
Accounts payable   $ 2,567     $ 3,799    
Accrued liabilities      8,751        9,949    
Deferred income      92        1,654    
Current portion of loans payable      81        79    
Total current liabilities      11,491        15,481    
Long-term portion of loans payable      344        386    
Contingent purchase price consideration      1,428        1,293    
Total liabilities      13,263        17,160    
         
Shareholders’ equity:        
Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at June 30, 2016 and December 31, 2015, and 22,569,104 and 22,549,488 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively      243        243    
Additional paid-in capital      246,504        244,033    
Accumulated deficit      (159,802 )      (146,307 )
Accumulated other comprehensive loss      (6,550 )      (5,277 )
Total shareholders’ equity      80,395        92,692    
Total liabilities and shareholders’ equity   $ 93,658     $ 109,852    
         
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 154

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
191 Schools Honored for Academic Growth Success

Updated Category News Views 65

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 22

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 17

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 146

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 101

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading

Top 5 Most Recently Viewed Articles

Actuate Therapeutics Achieves Notable Index Inclusion Milestone

Updated Category News Views 177

Actuate Therapeutics Celebrates Inclusion in Renowned Russell Indexes This recent inclusion exemplifies the rising momentum of Actuate Therapeutics, Inc. (NASDAQ: ACTU) as the company strives to innovate treatments for challenging cancers such as metastatic pancreatic ductal adenocarcinoma (mPDAC). The addition to the Russell 3000® Index and, by extension, the Russell...

Continue Reading
Insights on the Future Direction of Stora Enso's Leadership

Updated Category News Views 421

Proposals for Stora Enso Oyj's Board of Directors STORA ENSO OYJ STOCK EXCHANGE RELEASE - The Shareholders' Nomination Board has shared recommendations ahead of Stora Enso Oyj's upcoming Annual General Meeting. These proposals, made public well in advance, prepare the ground for a comprehensive evaluation of the company's leadership. The Board will ask for approval of its...

Continue Reading
Daisy Unveils Expansion Plans with NJ Smart Home Conversion

Updated Category News Views 200

Daisy Unveils Expansion Plans with NJ Smart Home Conversion Daisy franchisee brings expertise in advanced video walls and home entertainment systems Daisy, the fastest growing national home and small business technology installation and services company, is pleased to announce the conversion of NJ Smart Home & Theater into a franchise operation. This strategic move...

Continue Reading
You.com Partners with Boardwave to Revolutionize AI Productivity

Updated Category News Views 104

You.com and Boardwave Collaborate for AI Innovation You.com, an AI productivity platform, has recently announced an exciting partnership with Boardwave, a prominent network of over 1,700 software leaders across Europe. This collaboration aims to boost productivity and facilitate the integration of artificial intelligence throughout the European software landscape....

Continue Reading
Goldmoney Inc.'s Q3 Performance and Financial Restatement Update

Updated Category News Views 374

Financial Performance of Goldmoney Inc. Goldmoney Inc. (TSX: XAU) recently released its financial results for the fiscal 2025 third quarter, showcasing a robust performance despite challenges in the market. With all figures reported in Canadian dollars, the company evidenced strength through its tangible capital and efficient management of resources. Quarterly Financial...

Continue Reading